Psychedelic experience intensity during ketamine treatment and antidepressant outcomes

RATIONALE: Ketamine is an effective antidepressant, but the role of acute subjective effects in treatment response remains unclear. Prior studies rely largely on dissociation measures focused on adverse events, which may not capture broader effects across multiple phenomenological domains. OBJECTIVES: To evaluate whether subjective psychedelic intensity during ketamine treatment, considered beyond an adverse-event framework, is associated with antidepressant outcomes. METHODS: In this retrospective longitudinal cohort study, 3,637 adults with moderate-to-severe depression received up to 4 doses of sublingual ketamine over 4 weeks within a telehealth-supported treatment program. Subjective effects were assessed using the Mindbloom Psychedelic Intensity (MPI) scale, a novel 5-item measure capturing emotional, cognitive, physical, visual, and auditory effects. Primary outcomes included end-of-treatment change in Patient Health Questionnaire-9 (PHQ-9) scores, clinically significant change, and treatment response trajectories. Pre-registered analyses evaluated whether MPI scores at the midpoint of treatment were associated with antidepressant outcomes. RESULTS: Higher subjective intensity scores at 2 weeks were associated with greater reductions in depression severity at 4 weeks, increased likelihood of clinically significant change, and greater likelihood of membership in an improvement trajectory, independent of dose and other covariates. CONCLUSIONS: Subjective intensity of the ketamine experience was robustly associated with antidepressant outcomes. These findings suggest that subjective drug effects represent a clinically meaningful correlate of treatment response and highlight the importance of assessments designed to capture first-person experiences with ketamine, with implications for future mechanistic research and clinical care.

Authors

Institutions

Publication Details

Journal
Psychopharmacology
Published
2026-11-18
DOI
https://doi.org/10.1007/s00213-026-07219-0
Primary Topic
Treatment of Major Depression
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Psychedelic experience intensity during ketamine treatment and antidepressant outcomes

Sean P. Goldy, David S. Mathai, Matteo Malgaroli, Thomas D. Hull et al.
1 links
Psychopharmacology
Treatment of Major Depression
article

Psychedelic experience intensity during ketamine treatment and antidepressant outcomes

Sean P. Goldy, David S. Mathai, Matteo Malgaroli, Thomas D. Hull, Leonardo Vando, Kristin Arden, Jack Swain
article en

Abstract

RATIONALE: Ketamine is an effective antidepressant, but the role of acute subjective effects in treatment response remains unclear. Prior studies rely largely on dissociation measures focused on adverse events, which may not capture broader effects across multiple phenomenological domains. OBJECTIVES: To evaluate whether subjective psychedelic intensity during ketamine treatment, considered beyond an adverse-event framework, is associated with antidepressant outcomes. METHODS: In this retrospective longitudinal cohort study, 3,637 adults with moderate-to-severe depression received up to 4 doses of sublingual ketamine over 4 weeks within a telehealth-supported treatment program. Subjective effects were assessed using the Mindbloom Psychedelic Intensity (MPI) scale, a novel 5-item measure capturing emotional, cognitive, physical, visual, and auditory effects. Primary outcomes included end-of-treatment change in Patient Health Questionnaire-9 (PHQ-9) scores, clinically significant change, and treatment response trajectories. Pre-registered analyses evaluated whether MPI scores at the midpoint of treatment were associated with antidepressant outcomes. RESULTS: Higher subjective intensity scores at 2 weeks were associated with greater reductions in depression severity at 4 weeks, increased likelihood of clinically significant change, and greater likelihood of membership in an improvement trajectory, independent of dose and other covariates. CONCLUSIONS: Subjective intensity of the ketamine experience was robustly associated with antidepressant outcomes. These findings suggest that subjective drug effects represent a clinically meaningful correlate of treatment response and highlight the importance of assessments designed to capture first-person experiences with ketamine, with implications for future mechanistic research and clinical care.

Psychopharmacology
Johns Hopkins University (US), Baylor College of Medicine (US), Johns Hopkins Medicine (US), Max Planck Institute for Psycholinguistics (NL), New York University (US)
Good health and well-being
Treatment of Major Depression
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon